Anupam Rasayan has successfully completed the 100% acquisition of Jayhawk Fine Chemicals Corporation for approximately $150 million. The acquisition is financed through $129 million from Oaktree affiliate Altis XII and $21 million from Axis Bank, making it EPS accretive upon consolidation. Jayhawk, a US-based specialty chemical firm, provides high-performance materials to sectors like semiconductors and aerospace, with 65% of its revenue coming from these high-growth areas. This move significantly expands Anupam's global footprint and integrates its operations with Tanfac Industries for enhanced synergies.

Anupam Rasayan India Limited has successfully completed the acquisition of Monitchem Kansas S.à r.l. and its subsidiaries, including the US-based Jayhawk Fine Chemicals Corporation. The transaction was finalized on February 27, 2026, through its wholly-owned subsidiary, Doriath S.à r.l. This strategic move, which follows an agreement signed in December 2025, significantly expands the company's global footprint and manufacturing capabilities in the specialty chemicals sector. The integration of these assets is expected to provide a strong platform for growth in the North American market.

Anupam Rasayan has executed a facility agreement to raise USD 30 million through External Commercial Borrowing (ECB) from Axis Bank and other syndicated lenders. The proceeds are specifically earmarked to partially finance the acquisition of Monitchem Kansas S.à r.l. and associated costs. The loan is secured by a pari passu charge on the company's movable and immovable fixed assets and is effective from February 19, 2026. This financing follows recent regulatory amendments by the RBI regarding foreign exchange management.

Anupam Rasayan reported a robust 84% YoY growth in 9M FY26 revenue reaching ₹1,730 crores, driven by the scale-up of commercial molecules and improved capacity utilization. The company's PAT for the nine-month period rose 71% to ₹166 crores, while Q3 FY26 PAT grew 12% YoY to ₹61 crores. A significant strategic move was the announcement of the 100% acquisition of US-based Jayhawk Fine Chemicals, which is expected to be EPS accretive immediately upon closing. Segmental performance was strong, with the Performance Material vertical growing 245% YoY and Pharma growing 85% YoY during the first nine months.

Anupam Rasayan has executed definitive agreements to fund the acquisition of Monitchem Kansas S.à r.l. through its subsidiary Doriath. The financing structure includes a $30 million External Commercial Borrowing (ECB) for the parent company and a $20 million credit facility for Doriath. Additionally, Batam S.à r.l. will invest $110 million into Doriath to facilitate the transaction. To secure these facilities, Anupam Rasayan has provided corporate guarantees totaling $150 million and a non-disposal undertaking for its 25.8% stake in Tanfac Industries.

Anupam Rasayan reported a robust 9M FY26 performance with consolidated revenue growing 84% YoY to ₹17,297 million and PAT increasing 71% to ₹1,662 million. A major strategic highlight is the definitive agreement to acquire US-based Jayhawk Fine Chemicals for an enterprise value of $134 million, which is expected to significantly enhance its global footprint and performance materials portfolio. While Q3 FY26 revenue grew 31% YoY to ₹5,124 million, consolidated EBITDA margins compressed to 25% from 31% in the year-ago period. The acquisition will be funded through a mix of internal accruals, debt, and quasi-equity, creating a pro-forma entity with approximately $243 million in revenue.

Anupam Rasayan reported a robust 33% YoY increase in revenue for Q3FY26, reaching ₹5,145 million. Profit After Tax (PAT) grew by 12% YoY to ₹606 million, while EBITDA margins stood at 25.20%. A significant strategic development is the definitive agreement to acquire Jayhawk Fine Chemicals in the USA, aimed at strengthening their presence in North American regulated markets. The company continues to show strong momentum in its custom synthesis and specialty chemicals business with 9M FY26 revenue reaching ₹17,297 million.

Anupam Rasayan reported a strong year-on-year performance for Q3 FY26, with standalone revenue from operations rising 89% to ₹401.37 crore compared to ₹212.09 crore in the same quarter last year. Standalone Profit After Tax (PAT) surged by 150% YoY to ₹47.92 crore, although revenue saw a sequential decline from Q2 FY26. The company successfully utilized ₹277.5 crore from a preferential allotment for debt repayment and general corporate purposes. For the nine-month period, the company's performance shows a massive recovery with PAT reaching ₹119.01 crore compared to ₹34.58 crore in the previous year.

Anupam Rasayan has advanced its global expansion strategy by acquiring 100% of Doriath S.à r.l. and 15% of Batam S.à r.l. to facilitate the takeover of the Monitchem Kansas group, including Jayhawk Fine Chemicals. To fund this, the company has secured a USD 30 million ECB facility from Axis Bank and a USD 20 million credit facility for its subsidiary Doriath. This follows a previously approved shareholder limit of Rs. 4,500 crores for investments and guarantees. The company is leveraging its assets and shares in Tanfac Industries as security for these facilities.

Anupam Rasayan has finalized the financing and structural details for the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, including Jayhawk Fine Chemicals. The company has secured a $30 million External Commercial Borrowing (ECB) from Axis Bank and a $20 million credit facility for its subsidiary, Doriath S.à r.l. These funds will be used to complete the international acquisition, with the board also approving corporate guarantees and asset charges to secure the debt. This follows a prior shareholder mandate allowing for investments and guarantees up to Rs. 4,500 crores.

Shareholders of Anupam Rasayan India Limited have passed three key special resolutions via postal ballot with over 99.6% majority. The company has secured approval to increase its borrowing limits to ₹4,500 Crores and has similarly increased its limits for investments, loans, and guarantees to ₹4,500 Crores. Additionally, the board is now authorized to mortgage or charge company assets to secure these borrowings. This significant increase in financial headroom suggests the company is positioning itself for major capital expenditure or strategic acquisitions.

Anupam Rasayan India Limited has successfully passed three key special resolutions via postal ballot with overwhelming shareholder support. The resolutions grant the company authority to increase its overall borrowing limits and to sell, lease, or mortgage company undertakings. Additionally, shareholders approved exceeding statutory limits for investments, loans, and guarantees under Section 186 of the Companies Act. These approvals provide the management with significant financial flexibility to fund future growth and strategic initiatives.

Anupam Rasayan has signed a definitive agreement to acquire 100% of US-based Jayhawk Fine Chemicals for an enterprise value of $134 million, representing a 9x CY24 EBITDA multiple. Jayhawk reported revenues of $78 million in CY24 with a 19% EBITDA margin, specializing in high-value performance materials and life sciences. The deal is funded via $40 million from internal accruals/debt and $110 million from a global investment firm through non-voting shares. This strategic acquisition establishes a direct US manufacturing presence and is expected to be EPS-accretive from day one.

Anupam Rasayan India Limited (ANURAS) has announced the acquisition of 100% equity in Jayhawk Fine Chemicals LLC, a U.S.-based specialty chemicals company, for an enterprise value of approximately $134 million. The total purchase consideration is ~$150M, which includes ~$16M of cash & cash equivalents on Jayhawk’s balance sheet. Jayhawk's revenue for 2024 was ~$78M with an EBITDA of ~$15M, representing a margin of approximately 19%. The acquisition will be funded through a combination of internal accruals, debt, and quasi-equity.